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BACKGROUND: The objective was to assess the efficacy and safety of splenectomy
and cyclophosphamide as salvage therapies in severe thrombotic thrombocytopenic
purpura (TTP).STUDY DESIGN AND METHODS: During a 10-year period, patients
who did not improve with plasma exchanges, steroids, vincristine, and/or rituximab
were considered for splenectomy or cyclophosphamide. Patients with a documented
severe (<10% of normal value) acquired ADAMTS13 deficiency are reported here.
RESULTS: Eighteen patients with a severe acquired ADAMTS13 deficiency required
a salvage therapy. Thirteen patients had a splenectomy 19 (interquartile range [IQR],
10-51) days after TTP diagnosis. One patient died the day after splenectomy. The
remaining patients improved platelets (PLTs) until Day 6, along with a rapid and
major lactate dehydrogenase improvement. Six patients, however, subsequently
experienced a transient worsening. Durable PLT count recovery in survivors was
observed within 13 (IQR, 11.5-25.5) days. Postoperative complications included
thromboembolic events (two cases) and infections (five cases). Five patients received
pulses of cyclophosphamide 12 (IQR, 12-15) days after TTP diagnosis. All patients
recovered PLTs 10 (IQR, 9-24) days after the first pulse and two experienced a
transient worsening. Three patients experienced infections. Three relapses occurred
5 months, 2.5 years, and 4.5 years after splenectomy and one relapse occurred 3.5
years after cyclophosphamide. After a 2.5 (IQR, 0.75-6.2)-year follow-up, the overall
survival was 94%. CONCLUSION: Cyclophosphamide and splenectomy provide
comparable high remission rates in severe TTP with acceptable side effects and
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